Health Companies
Neuropacs ๐บ๐ธ 
Chai Discovery ๐บ๐ธ 
Myfitnesspal ๐บ๐ธ 
Paradigm Health ๐ 
Delphyr ๐ณ๐ฑ 
Medpal ๐ฌ๐ง 
Avenue Biosciences ๐ซ๐ฎ 
Bit.bio ๐ฌ๐ง 
Torch ๐บ๐ธ 
Gardia ๐ฉ๐ช Latest Deals in Health
FLUOSPHERA
$80M
Apella, a health technology company, has raised $80 million in Series B financing to scale its ambient AI platform that automates surgical workflow data using computer vision. The funding round was led by HighlandX and included returning investors such as Vensana Capital and Casdin Capital, along with new investors like K2 Healthventures. HighlandX partner Corey Mulloy will join Apella's board as part of the deal.
APELLAInvestors: HighlandX, Vensana Capital, Casdin Capital, K2 Healthventures
$20M
Tucuvi has raised $20 million in Series A funding to enhance its AI care management platform, addressing challenges such as workforce shortages and rising demand in healthcare. The funding round was co-led by Cathay Innovation and KFund, with participation from Frontline Ventures, Seaya Ventures, and Shilling.
TUCUVIInvestors: Cathay Innovation, KFund, Frontline Ventures, Seaya Ventures, Shilling
BRIGHTHEART
$22.356M
Enodia Therapeutics has raised โฌ20.7 million (approximately $25 million) in seed financing to enhance its discovery platform that utilizes proteomics and machine learning for developing small molecules that degrade disease-driving proteins. The funding round was co-led by Elaia, Pfizer Ventures, and Bpifrance, with additional participation from various investors including Wallonie Entreprendre and the Institut Pasteur.
ENODIA THERAPEUTICSInvestors: Elaia, Pfizer Ventures, Bpifrance, Wallonie Entreprendre, Institut Pasteur
VERANA HEALTH
TRIALBEE
$20M
Tucuvi, a Madrid, Spain-based developer of a voice AI platform for automating clinical care management workflows, raised $20 million in Series A funding. The round was co-led by Cathay Innovation and Kibo Ventures, with participation from Frontline Ventures, Seaya Ventures, and Shilling. The funds will be used to accelerate international expansion, particularly in the United Kingdom and the United States, and to enhance its AI technology for managing more complex clinical use cases.Investors: Cathay Innovation, Kibo Ventures, Frontline Ventures, Seaya Ventures, Shilling
$4.6M
Oasys Health, an AI-native operating system for behavioral health, raised $4.6 million to enhance its platform that integrates practice management, clinical decision support, and real-time data from wearables. The funding includes a $4 million seed round led by Pathlight Ventures, with participation from Twine Ventures and Better Ventures, along with $600,000 in pre-seed funding from 1984 Ventures.
OASYSInvestors: Pathlight Ventures, Twine Ventures, Better Ventures, 1984 Ventures
$20M
Tucuvi, a Spanish AI voice startup, has raised $20 million in a Series A funding round to enhance its AI care management platform, which automates clinical workflows during patient calls. Founded by Maria Gonzalez, the funding was led by Cathay Innovation and Kfund, with participation from Frontline Ventures, Seaya Ventures, and Shilling. Tucuvi's technology supports over 50 workflows and has already completed over 300,000 patient calls, aiming to expand across Europe and the US.Investors: Cathay Innovation, Kfund, Frontline Ventures, Seaya Ventures, Shilling
$11.88M
Brightheart, a Paris, France-based company specializing in AI solutions for prenatal ultrasound, raised โฌ11 million in Series A funding. The round was led by Odyssรฉe Venture and Go Capital, with participation from the Mussallem CHD Alliance, Lift Value, Idaho Healthtech Club via Side Angels, and founding investor Sofinnova Partners, along with clinicians and angel investors.Investors: Odyssรฉe Venture, Go Capital, Mussallem CHD Alliance, Lift Value, Idaho Healthtech Club via Side Angels, Sofinnova Partners
RAKUTEN MEDICAL
CARNA HEALTH
$11.88M
Brightheart raised โฌ11 million in Series A funding to enhance prenatal care by improving the detection of congenital heart defects through its b-right AI platform. Co-led by Odyssรฉe Venture and Go Capital, the funding will help expand its market presence in the US and Europe, following five FDA clearances and promising clinical trial results showing over 96% accuracy in defect detection. Key investors include the Mussallem CHD Alliance and Sofinnova Partners.Investors: Odyssรฉe Venture, Go Capital, Mussallem CHD Alliance, Sofinnova Partners
VICENTRA
SPORE.BIO
$775.44M
UK-based Dark Blue Therapeutics, a biotech company focused on precision oncology, has been acquired by US biotech giant Amgen in a deal valued at up to โฌ718 million ($840 million). The acquisition aims to accelerate the development of Dark Blue's lead candidate, dbt-3757, a first-in-class therapy for leukemia. Key investors include Oxford Science Enterprises, Bristol Myers Squibb, and Evotec, highlighting the strong investment landscape in oncology.
DARK BLUE THERAPEUTICSInvestors: Oxford Science Enterprises, Bristol Myers Squibb, Evotec